Mipeginterferon Alfa-2b, marketed under the brand name Pegbing, represents a significant advancement in the treatment of chronic hepatitis B. As the first 40kD Y-shape PEG-modified interferon alfa-2b injection in the world, it stands out due to its unique structure and complete patent protection. This groundbreaking product has broken the monopoly of foreign treatments in viral hepatitis and has been recognized with prestigious awards for its innovation. Pegbing offers improved efficacy and a favorable safety profile, making it a preferred choice for clinicians and patients. Developed over 14 years of dedicated research by Amoytop Biotech, Mipeginterferon Alfa-2b is poised to lead the market in hepatitis B treatment and contribute significantly to the goal of achieving a clinical cure for chronic hepatitis B.
Specialized in R&D and production of recombinant protein drugs, and committed to providing better solutions for viral hepatitis, malignant tumor and immunotherapy etc..
